Biogen's new Alzheimer's drug serves as a rallying cry for drug pricing reforms

A coalition of employers and health care purchasers are calling on the top House and Senate leaders to take a hard look at the “astronomical price” of Biogen’s new Alzheimer’s drug Aduhelm and “move boldly” to enact prescription drug pricing reform.